Sensor-Based Digital Therapeutics Devices Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Sensor-Based Digital Therapeutics Devices Market in 2026?

USD 249.6 million in 2026 and USD 590.9 million by 2036 at a 9.0% CAGR.

Demand for sensor-based digital therapeutics devices is projected to expand at 9.0% CAGR between 2026 and 2036, increasing valuation from USD 249.6 million in 2026 to USD 590.9 million by 2036. Regulatory initiatives aimed at modernizing oversight of digital health technologies are improving the commercial outlook for sensor-enabled therapeutic devices. The FDA launched TEMPO in December 2025 to test risk-based pathways for selected digital health devices used in chronic disease management. In July 2026 the agency selected Dexcom as the first participant and required real-world data collection for the reviewed intended use. The pilot provides a clearer route for systems that connect sensor measurements with software guidance and defined clinical responsibilities. Commercial adoption becomes more defensible through measurable device outputs and a treatment pathway that health systems can supervise.

United States providers can connect regulated devices with Medicare payment pathways for qualifying digital treatments used within behavioral health care. CMS expanded payment for digital mental health treatment devices used for attention deficit hyperactivity disorder through its October 2025 final rule. German access follows the separate DiGA route, eligible applications require structured BfArM review and evidence of positive care effects. BfArM released version 3.6 of its DiGA fast-track guide in December 2025 with updated application and evidence requirements. United Kingdom developers must manage registration and continuing surveillance duties across NHS service environments and prescribing organizations. Commercial teams therefore need country-specific evidence plans and support arrangements rather than one launch package for every geography.

Key Takeaways

• Regulated treatment pathways and payer coverage are expanding demand for devices that connect continuous measurements with guided therapeutic actions and accountable follow-up.
• Software is expected to account for 41.8% in 2026, reflecting its central role in sensor-based digital therapeutics, it interprets sensor inputs and coordinates personalized interventions across care pathways.
• Hospitals are projected to represent 28.0% in 2026, owing to their established clinical governance frameworks, these structures support timely escalation for abnormal readings and treatment-related issues.
• Monitoring is anticipated to capture 26.0% of application demand in 2026, driven by the need for continuous patient assessment.
• Clinical integration and post-market surveillance obligations create material barriers for developers seeking repeat deployment across multiple health systems and reimbursement routes.
• Competition includes MedRhythms, Cala Health, Omada Health, Hinge Health, Biofourmis, Theranica, Resmed, and Welldoc across prescription therapies and connected care programs.

Analyst Perspective

“A sensor-based therapeutic earns recurring use through accurate measurement and a defined clinical response for every important reading. Health systems compare evidence quality with alert burden and integration effort across the complete care pathway. They also examine reimbursement fit and service ownership during program selection for continuing patient treatment. Developers that connect reliable sensing with clear escalation rules can convert controlled deployments into repeatable treatment programs.”

- Anurag Sharma, Principal Analyst, Future Market Insights

How is the sensor-based digital therapeutics devices market segmented?

The sensor-based digital therapeutics devices industry is segmented by product type, care setting, application, end user, and region.

The market is segmented by product type, care setting, application, end user, and region for detailed commercial analysis. Product type covers software, wearables, diagnostic kits, consumables, and device accessories that support therapeutic programs. Care setting separates hospitals, home care, ambulatory centers, retail clinics, and decentralized trial sites according to oversight and service needs. Application includes monitoring, diagnosis, workflow automation, therapy support, and infection control across regulated treatment pathways and services. End user distinguishes hospitals, payers, diagnostic laboratories, medtech firms, and patients that finance or operate each program. Regional analysis reflects authorization, reimbursement, integration capacity, and technical support across major countries and commercial entry routes. The taxonomy also links sensor-guided treatment with adjacent wearable medical devices used across regulated care pathways.

Why does software support the largest product type share?

Software translates sensor readings into patient guidance and records that clinicians can evaluate during continuing treatment. Welldoc began powering the Lilly Health platform in June 2025 with device connectivity and health-data tracking for selected incretin therapies. The launch shows how home healthcare software can connect measurements with medication support without placing data inside separate applications. Continuous glucose monitoring and connected scales provide repeated inputs that software must place within one patient record. Developers also need clear escalation logic and secure data exchange across connected clinical workflows and provider systems.

• Software is projected to hold 41.8% share in 2026 owing to its control over data interpretation and therapeutic guidance. The code combines measurements from several regulated devices and applies condition-specific rules across one patient pathway. Recurring licenses and updates strengthen software spending beyond the initial device purchase throughout continuing treatment.
• Health plans and clinical teams adopt configurable software that supports several conditions without separate enrollment systems for every program. Unified workflows reduce duplicate training and give care teams one location for engagement and escalation review. Adoption weakens if data enter a separate dashboard that cannot exchange records with clinical systems.

How does hospital shape demand within the care setting category?

Hospitals carry responsibility for clinical escalation if sensor readings reveal deterioration or a treatment problem requiring immediate review. Their governance structures assign alert ownership and allow specialty teams to change treatment under established protocols. Sensor-based programs must connect bedside and home readings with the clinical records that responsible teams already use. Health systems therefore assess integration ownership and clinical staffing ahead of expansion across specialties and service lines.

• The care setting category is forecast to be led by hospital at 28.0% share in 2026 due to established clinical governance and escalation capacity. Biofourmis announced an AdventHealth acute care-at-home collaboration in January 2025 using remote patient monitoring and FDA-cleared algorithms. The deployment demonstrates why institutions with defined clinical ownership can validate sensor-guided treatment across hospital and home settings.
• Hospital groups often begin with specialty services that can measure outcomes and resolve adverse readings under controlled protocols. Successful programs require biomedical engineering support and an accountable clinical owner for alerts and software changes. Expansion becomes difficult if maintenance coverage or record integration remains unclear across departments and affiliated home-care services.

What supports monitoring demand within the application category?

Monitoring creates a longitudinal record that connects treatment use with symptoms and physiological response between scheduled encounters. Omada Health added cholesterol management to its integrated platform in February 2026 alongside weight and glucose support. The launch shows how continuous glucose monitoring can inform continuing care across related cardiometabolic conditions instead of separate programs. Clinical teams must filter routine variation from actionable change so monitoring improves decisions without adding excessive review work.

• By application, monitoring is estimated to hold 14.0% share in 2026 owing to its role in documenting treatment response across repeated measurements. Longitudinal records help clinicians compare current results with prior baselines and identify changes that require intervention. The segment gains commercial value through continuing evidence between visits instead of isolated readings collected during appointments.
• Care programs favor monitoring functions that prioritize clinically relevant changes and preserve a complete record for later review. Reliable thresholds reduce repetitive alerts and help clinicians direct attention toward patients who require intervention. Adoption slows if sensor accuracy varies or alert logic cannot match the treatment protocol used by the responsible care team.

What are the drivers, restraints, and opportunities in the sensor-based digital therapeutics devices market?

Regulated care pathways are widening access to sensor-guided treatment, while integration burdens and evidence obligations continue to limit repeat deployment.

• Driver: Regulated prescription pathways create defined purchasing routes for devices that connect sensor measurements with therapeutic actions and documented clinical outcomes.
• Restraint: Clinical integration and post-market surveillance requirements create continuing service obligations beyond initial device authorization or software deployment.
• Opportunity: Interoperable health data networks allow developers to connect sensor records with longitudinal care pathways and outcome-based service models.

Regulated prescription pathways are strengthening demand for devices that pair sensors with a defined therapeutic response. MedRhythms announced FDA Class II listing for Movive in March 2025 to support gait rehabilitation and motor function in Parkinson’s disease. The listing created a route for a home-use neurostimulation platform that combines movement sensors with rhythmic auditory stimulation. Clinical teams support purchasing decisions through clear patient criteria and evidence that device output changes treatment. Wellness products without regulated therapeutic claims or accountable prescribing pathways face weaker adoption across clinical treatment programs.

Post-market obligations is one of the notable restraint for clinical software and connected devices that require continuing safety oversight beyond initial authorization. The MHRA implemented stronger Great Britain surveillance regulations in June 2025 and required manufacturers to track performance during commercial use. Device teams must maintain complaint handling and corrective action routes alongside cybersecurity and software updates. Smaller developers face heavier service burdens across jurisdictions with separate reporting systems and local representation duties. Adoption slows if a health system cannot identify responsibility for incident review or long-term technical maintenance.

Interoperable public infrastructure creates a commercial opening for therapeutics that exchange consented records across participating providers. India reported in May 2026 that more than 100 crore health records were linked with ABHA and over 450 technology solutions had integrated with ABDM. The national network can preserve treatment context across participating facilities through consent-based health information exchange. Developers must complete technical integration with consent-based exchange components before treatment data can enter connected records through national interfaces. Commercial value increases through sensor outputs that follow the patient across providers instead of remaining inside one isolated application.

Which country CAGRs are profiled in the sensor-based digital therapeutics devices market?

Country	CAGR
India	12.2%
China	11.3%
United States	10.4%
Germany	9.5%
Japan	8.6%
United Kingdom	7.7%

How do country-level CAGRs compare in the sensor-based digital therapeutics devices market?

The country forecasts show a clear progression across the sensor-based digital therapeutics devices market, with each successive market reflecting a gradual shift in adoption conditions rather than sharply defined growth tiers. India and China form the upper band of the comparison, supported by expanding digital health ecosystems, growing chronic disease burdens and increasing use of connected monitoring technologies. The United States follows closely behind and serves as a bridge between the higher-growth Asian markets and the more established healthcare environments of Europe and Japan. Germany, Japan and the United Kingdom create a lower grouping where differences are incremental rather than pronounced.

• India benefits from rapid expansion of digital healthcare services and increasing deployment of connected health technologies that support remote disease management and patient engagement.
• China's outlook is supported by large-scale adoption of digital health platforms and growing investment in technologies that combine sensor monitoring with clinical decision support.
• The United States reflects a mature innovation environment where regulatory initiatives, real-world evidence generation and established digital health companies continue to advance sensor-based therapeutic solutions.
• Germany continues to support adoption through increasing acceptance of digital health tools and the integration of data-driven care models within healthcare delivery systems.
• Japan's market development is influenced by demand for chronic disease management solutions and growing interest in technologies that support continuous monitoring and preventive care.
• The United Kingdom maintains steady momentum as healthcare providers evaluate digital therapeutic approaches that can improve patient outcomes while supporting more efficient care pathways.

Similar CAGRs do not necessarily create similar commercialization environments for sensor-based digital therapeutics devices. Differences in reimbursement frameworks, digital health regulations, clinical validation requirements and healthcare infrastructure can significantly influence adoption timelines and market access strategies. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• India uses ABDM to exchange consented digital records across registered facilities and technology platforms that meet national integration requirements. In India, sensor-based digital therapeutics device demand is predicted to advance at 12.2% CAGR through 2036, supported by broader use of ABDM-enabled software. The Press Information Bureau reported in February 2025 that 159,020 health facilities used ABDM-enabled software across every state and union territory. The installed route supports longitudinal records and consent-based exchange across participating treatment programs and registered clinical settings. Assisted and offline options improve enrollment across areas with unreliable connectivity and limited digital support. Technology platforms must integrate with ABDM consent and record-exchange components before treatment data can enter participating systems through approved interfaces. Commercial plans need local implementation partners that manage uneven technical capacity beyond major hospital networks.
• China requires overseas device developers to align registration and local representation with national medical device rules for commercial distribution. Provincial hospital access and service coverage vary across regions with different purchasing and maintenance arrangements. Adoption of sensor-based digital therapeutics devices in China is estimated to expand at 11.3% CAGR through 2036, shaped by evolving domestic production pathways. The NMPA issued a March 2025 announcement that optimized domestic production routes for certain imported Class II and Class III devices. Qualified manufacturers can shorten supply routes and strengthen maintenance access through approved domestic production for local service teams. Applicants must provide registration dossiers and quality-system equivalence evidence across overseas and domestic production locations. Distribution plans require regional technical support across provinces with different hospital access requirements and purchasing routes.
• The United States combines FDA authorization with Medicare and commercial benefit pathways for prescribed home-use systems. Sensor-based digital therapeutics device demand in the United States is forecast to rise at 10.4% CAGR over the forecast period, driven by specialty distribution and product-specific payment routes. MedRhythms reported in January 2025 that CMS issued a final Medicare payment determination for its InTandem rehabilitation system. CMS explains that new DMEPOS items receive benefit-category and payment determinations through a public process with a defined pricing hierarchy. The route can standardize payment for qualifying prescription devices without extending coverage to every digital therapeutic. Developers need billing support and patient onboarding with documentation that matches each health plan’s eligibility rules.
• Germany uses the BfArM DiGA fast-track route for eligible digital applications seeking directory listing and statutory reimbursement. Applicants must provide evidence of positive care effects with data protection controls that meet national requirements. Germany’s sensor-based digital therapeutics devices outlook is anticipated to advance at 9.5% CAGR over the assessment period, underpinned by a defined reimbursement route. BfArM’s January 2026 status graphic recorded 246 applications and 58 final-listing applications within the process. The figures show substantial commercial interest alongside meaningful attrition, so market entry requires German-language documentation and comparative evidence that withstands insurer and regulator scrutiny.
• Japan regulates therapeutic software as a medical device and expects developers to coordinate approval with a suitable domestic commercialization route. Sensor-based digital therapeutics device sales in Japan are forecast to expand at 8.6% CAGR by 2036, linked to continuing support for innovative SaMD review. Priority review can improve consultation and evaluation for products that meet innovation and clinical need criteria. PMDA stated in June 2026 that priority SaMD designation applications would be accepted continuously from fiscal 2026. Local partners remain important for Japanese documentation and clinician education across hospitals with established approval processes. Commercial teams should test interfaces and service procedures against local workflows during initial clinical deployments.
• The United Kingdom combines NHS evidence review with Great Britain registration and strengthened post-market reporting duties for regulated software devices. The MHRA published digital mental health guidance in August 2025 that explained adverse-event reporting duties for regulated software. The United Kingdom sensor-based digital therapeutics devices sector is projected to record 7.7% CAGR during the assessment period, owing to structured review and service capacity. Clearer guidance supports safer clinical deployment by defining reportable incidents and continuing manufacturer responsibilities for regulated software. Limited integration resources across NHS organizations can extend implementation schedules and increase the need for local incident response and technical support. Commercial plans should allow longer deployment periods across services with limited specialist capacity for continuing review.

Who are the notable companies in the sensor-based digital therapeutics devices market?

MedRhythms, Cala Health, Omada Health, Hinge Health, Biofourmis, Theranica, Resmed, and Welldoc compete across prescription neuromodulation, connected chronic care, and home monitoring programs.

The competitive field spans prescription neuromodulation and integrated chronic care platforms that support treatment across home and clinical settings. Hinge Health reported in May 2026 that its client count reached 2,849 during the first quarter. The figure shows the account reach available to introduce sensor-guided care through existing employer and health plan channels. MedRhythms, Cala Health, and Theranica focus on prescription neuromodulation with condition-specific home treatment protocols for eligible neurological conditions. Omada Health, Hinge Health, and Welldoc combine connected devices with continuing digital care across cardiometabolic or pain programs and health plan channels. Biofourmis and Resmed emphasize remote clinical workflows that depend on monitoring infrastructure and dependable service support through connected care platforms.

• MedRhythms and Cala Health focus on regulated neuromodulation devices that connect sensor or stimulation functions with condition-specific treatment protocols. Both companies require prescription access and patient support, their commercial differentiation depends on clinical evidence and fulfillment arrangements for home use.
• Omada Health, Hinge Health, and Welldoc combine connected devices with digital coaching or clinical support across employer and health plan channels. Their platforms compete through multi-condition workflows and national account relationships that reduce separate enrollment processes across related care programs.
• Biofourmis, Theranica, and Resmed compete through remote clinical workflows or prescription wearables that require coordinated monitoring and continuing service support. Commercial performance depends on how reliably each company connects device data with clinical action and patient access across supported geographies.

Competitive Benchmarking: Sensor-Based Digital Therapeutics Devices Market

Company	Regulated Therapeutic Capability	Sensor and Device Integration	Delivery and Access Support	Geographic Reach
MedRhythms	High	High	Medium	United States
Cala Health	High	High	Medium	United States
Omada Health	Medium	High	High	United States
Hinge Health	High	High	High	United States
Biofourmis	Medium	High	High	United States
Theranica	High	High	High	United States and China
Resmed	High	High	High	Global
Welldoc	High	High	High	United States

Scoring basis: Regulated therapeutic capability is High for an active regulated treatment device and Medium for a regulated supporting platform, Low requires verified limited treatment functionality. Sensor and device integration is High for direct device data inside the care workflow and Medium for selected connected inputs, Low requires verified narrow integration. Delivery and access support is High for documented multi-account distribution and Medium for narrower commercial coverage, Low requires verified limited service reach. Every rating requires official evidence, Low never represents missing research or an unverified capability within the exact market.

Key Developments in the Sensor-Based Digital Therapeutics Devices Market

• In April 2026, Hinge Health launched a comprehensive migraine care program that combined its FDA-cleared Enso wearable with trigger management and expert-led prevention. The company reported that more than 125 clients covering over two million people had already adopted the program. The launch extended an established employer care channel into sensor-guided migraine treatment with integrated clinical and digital support.
• In September 2025, Theranica and Pier 88 Health announced China NMPA approval for the Nerivio remote electrical neuromodulation wearable used for acute migraine treatment. The approval created a regulated route for a prescription therapy within China and supported structured physician-led commercialization. Expansion requires physician education and local distribution that can manage patient onboarding and repeat treatment access across participating treatment centers.
• In March 2026, Cala Health received FDA clearance for Cala kIQ Plus as a Class II external upper limb tremor stimulator. The prescription wrist-worn device is indicated for temporary relief of hand tremors in adults with essential tremor and selected hand tremor symptoms in adults with Parkinson’s disease. The clearance extends the company’s regulated TAPS platform across two neurological conditions through one home-use wearable. Commercial rollout requires clinician education and patient training alongside fulfillment support that supports consistent setup and therapy use.
• In April 2025, MedRhythms announced that Movive became available to eligible veterans living with Parkinson’s disease through a dedicated national federal access channel. The prescription device delivers rhythmic auditory stimulation through sensors and software during home-based walking sessions. The development extended a regulated digital therapeutic beyond standard commercial coverage and required coordinated prescribing with fulfillment and ongoing patient support nationwide.

Key Players in the Sensor-Based Digital Therapeutics Devices Market

Regulated Therapeutic Device Developers

• MedRhythms
• Cala Health
• Theranica

Integrated Digital Care Platforms

• Omada Health
• Hinge Health
• Welldoc

Clinical Monitoring and Home Care Platforms

• Biofourmis
• Resmed

Sensor-Based Digital Therapeutics Devices Market - Report Scope

Coverage field	Report scope
Market breakdown	Product type, care setting, application, end user, and region.
Quantitative Units	Revenue in USD Million, CAGR in %.
Market Definition	Commercial demand for regulated or clinically deployed digital therapeutic devices that combine sensor inputs with software-guided therapeutic intervention, monitoring, or treatment support.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	United States, Germany, United Kingdom, Japan, China, India, and 30+ countries.
Key Companies Profiled	MedRhythms, Cala Health, Omada Health, Hinge Health, Biofourmis, Theranica, Resmed, and Welldoc.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Sensor-Based Digital Therapeutics Devices Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Sensor-Based Digital Therapeutics Devices Market by Segments

Sensor-Based Digital Therapeutics Devices Market segmented by Product Type:

• Software
• Wearable
• Diagnostic Kit
• Consumable
• Device Accessory

Sensor-Based Digital Therapeutics Devices Market segmented by Care Setting:

• Hospital
• Home Care
• Ambulatory Center
• Retail Clinic
• Decentralized Trial Site

Sensor-Based Digital Therapeutics Devices Market segmented by Application:

• Monitoring
• Diagnosis
• Workflow Automation
• Therapy Support
• Infection Control

Sensor-Based Digital Therapeutics Devices Market segmented by End User:

• Hospitals
• Payers
• Diagnostic Labs
• Medtech Firms
• Patients

Sensor-Based Digital Therapeutics Devices Market by Region:

• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan and Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East and Africa

Research Sources and Bibliography

• U.S. Food and Drug Administration. (2025, December 5). FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies.
• U.S. Food and Drug Administration. (2026, July 22). FDA Announces First Participant Selected for TEMPO for Digital Health Devices Pilot.
• Centers for Medicare & Medicaid Services. (2025, October 31). Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).
• Federal Institute for Drugs and Medical Devices. (2025, December 11). DiGA (Digitale Gesundheitsanwendungen)-Leitfaden (Stand: 10.12.2025, Version 3.6).
• Welldoc. (2025, June 4). Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly’s Incretin Therapies.
• Biofourmis. (2025, January 6). Biofourmis Selected by AdventHealth to Support “Whole-Person Care” With New Acute Care-at Home Program.
• Omada Health. (2026, February 19). Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk.
• Theranica. (2026, February 4). Theranica Announces U.S. Coverage for Nerivio® Reaching ~130 Million Lives, Attaining Payer Scale Comparable to Leading Migraine Drugs.
• Resmed. (2025, December 8). Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy.
• MedRhythms. (2025, March 6). MedRhythms Announces FDA Class II Listing for Movive™ to Support Gait Rehabilitation and Motor Function for Parkinson’s Disease.
• Medicines and Healthcare products Regulatory Agency. (2025, June 16). First major overhaul of medical device regulation comes into force across Great Britain.
• Press Information Bureau. (2026, May 22). 100 Crore Health Records Linked with ABHA under ABDM, Marking Major Leap in Digital Healthcare.
• Press Information Bureau. (2025, February 11). Update on the implementation of Ayushman Bharat Digital Mission (ABDM).
• National Medical Products Administration. (2025, March 17). NMPA Announcement on Further Improvement and Optimization of Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China (No. 30, 2025).
• MedRhythms. (2025, January 16). MedRhythms’ InTandem® Rehabilitation System for Chronic Stroke Gait Impairment Receives Final Medicare Payment Determination from CMS.
• Centers for Medicare & Medicaid Services. (2025, May 5). DMEPOS Payment Determinations for New Items & Services.
• Federal Institute for Drugs and Medical Devices. (2026, January 14). Interesting facts.
• Pharmaceuticals and Medical Devices Agency. (2026, June 15). Trial Implementation of Priority Review of SaMD.
• Medicines and Healthcare products Regulatory Agency. (2025, August 1). Report on Adverse Event (AE) reporting in digital mental health technologies (DMHTs) and the development of updates to regulatory guidance.
• Hinge Health. (2026, May 5). Hinge Health reports record first quarter 2026 financial results.
• Hinge Health. (2026, April 29). Hinge Health launches comprehensive Migraine Care Program.
• Theranica. (2025, September 30). Pier 88 Health and Theranica Announce China NMPA Approval of the Nerivio® REN Wearable for Acute Treatment of Migraine.
• U.S. Food and Drug Administration. (2026, March 17). 510(k) Premarket Notification.
• MedRhythms. (2025, April 2). MedRhythms Announces Availability of Movive™ for Parkinson’s Disease (PD) for Veterans.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the sensor-based digital therapeutics devices market in 2026 and 2036?
• Which product types create defensible commercial demand across regulated care pathways?
• How does care setting influence clinical oversight and device integration responsibilities?
• Which applications support repeat purchasing through measurable therapeutic response?
• How do payers and other end users evaluate coverage and service responsibilities?
• How do country growth rates compare across different access environments?
• Which company capabilities matter most for competitive benchmarking in this market?
• Which regulatory and reimbursement changes influence commercial access for sensor-based therapies?
• How should health systems compare regulated device developers with integrated digital care platforms?